Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,368.46 -37.20 (-0.10%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,144.13 -2.90 (-0.04%) Bitcoin USD
60,204.73 -3,226.18 (-5.09%) CMC Crypto 200
1,289.74 -49.32 (-3.68%)
Alnylam Pharmaceuticals, Inc. (ALNY)
After hours:
- Zacks
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
- PR Newswire Asia
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets.
- Zacks
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
